Press Release
August 8, 2011
China Medical Technologies and Leica Microsystems Announce
Collaboration
Joint Sales, Research and Development
Beijing, China / Wetzlar, Germany. China Medical Technologies, Inc. (CMED) (Nasdaq: CMED), a leading
China-based advanced in-vitro diagnostic (“IVD”) company, and Leica Biosystems, a division of Leica
Microsystems, a world leader in microscopes and scientific instruments, today announced that they have
established a sales, research and development collaboration to co-develop and market automated FISH
kits to be used on the Leica BOND system. CMED will sell the Automated FISH Kits in China and Leica
will have an option to sell the FISH kits in the rest of the world.
Under the collaboration, CMED and Leica Microsystems will jointly develop automated FISH solutions for
tissue sample tests on HER-2, EGFR and TOP2A on the Leica BOND system, an automated advanced
staining platform. HER-2, EGFR and TOP2A are genes in connection with the targeted cancer therapy
drugs for breast cancer, lung cancer and stomach cancer patients. Automation of these FISH tests on the
Leica BOND system will enable pathology laboratories and independent service laboratories to run these
diagnostic tests more efficiently and with higher and more consistent quality. The automation of FISH
tests will also help users to reduce the work load pressure created by increasing test volumes. Both
parties agreed to add further FISH applications into the collaboration during the term, including for
cytology and pre-natal applications.
“These collaborations with Leica mark a significant milestone for us,” commented Mr. Xiaodong Wu,
Chairman and Chief Executive Officer of CMED. “We believe that FISH applications will be more widely
used in various clinical applications on automated basis in the future. By partnering with Leica, one of the
leading global players anatomic pathology, we can provide more efficient and higher quality FISH
diagnostic solutions to the end users not only in China, but also in the global markets through Leica’s
extensive global network.”
Dr. Kirstin Henze
Tel.: +49(0)6441/29-2550
Fax: +49(0)6441/29-2527
corporate.communications@leica-microsystems.com
Leica Microsystems GmbH
Ernst-Leitz-Straße 17-37
D – 35578 Wetzlar
www.leica-microsystems.com
1/2
Press Release
“CMED is the market leader for FISH based diagnostics in China and has played a key role in the rapid
development in the use of FISH in China, especially for tissue based companion diagnostic testing. This
partnership will help Leica and CMED to offer customers in China a broad test menu of high quality FISH
tests automated on the Leica BOND system,” commented Arnd Kaldowski, President of Leica
Biosystems.
_______________
Leica Microsystems is a world leader in microscopes and scientific instruments. Founded as a family
business in the nineteenth century, the company’s history was marked by unparalleled innovation on its
way to becoming a global enterprise. Its historically close cooperation with the scientific community is the
key to Leica Microsystems’ tradition of innovation, which draws on users’ ideas and creates solutions
tailored to their requirements. At the global level, Leica Microsystems is organized in four divisions, all of
which are among the leaders in their respective fields: the Life Science Division, Industry Division,
Biosystems Division and Medical Division.
Leica Microsystems’ Biosystems Division, also known as Leica Biosystems, offers histopathology
laboratories the most extensive product range with appropriate products for each work step in histology
and for a high level of productivity in the working processes of the entire laboratory.
The company is represented in over 100 countries with 12 manufacturing facilities in 7 countries, sales
and service organizations in 19 countries and an international network of dealers. The company is
headquartered in Wetzlar, Germany.
China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular
diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon
Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay
(ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various
cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The
Company generates all of its revenues in China through the sale of diagnostic consumables including
FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the
consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through
its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more
information, please visit http://www.chinameditech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking”
statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and
as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements
can be identified by terminology such as “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,”
“estimates” and similar statements. Among other things, the quotations from management in this press
release contain forward-looking statements. Such statements involve certain risks and uncertainties that
could cause actual results to differ materially from those in the forward-looking statements. Further
information regarding these and other risks is included in the Company's filings with the U.S. Securities
and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake
any obligation to update any forward-looking statement as a result of new information, future events or
otherwise, except as required under applicable law.
Contacts
Leica Microsystems
Dr. Kirstin Henze
Tel.: +49 – 6441 – 29 – 2550
Email: Kirstin.henze@leica-microsystems.com
Website: www.leica-microsystems.com
China Medical Technologies, Inc.
Sam Tsang and Winnie Yam
Tel: +852-2511-9808
Email: IR@chinameditech.com
Website: www.chinameditech.com
2/2